MAPT and Alzheimer disease: In conclusion, we developed new t-tau immunoassays for the Simoa platform targeting both N-terminal and mid-region epitopes of tau and showed that different t-tau assays have different biomarker potential in the Alzheimer’s disease continuum both in CSF and plasma.